about
Gold nanoparticles for cancer radiotherapy: a reviewDNA damage responses following exposure to modulated radiation fieldsBiological mechanisms of gold nanoparticle radiosensitization.Investigation into the radiobiological consequences of pre-treatment verification imaging with megavoltage X-rays in radiotherapyA kinetic-based model of radiation-induced intercellular signalling.Small animal image-guided radiotherapy: status, considerations and potential for translational impact.The use of theranostic gadolinium-based nanoprobes to improve radiotherapy efficacy.Imaging and radiation effects of gold nanoparticles in tumour cellsPhysical basis and biological mechanisms of gold nanoparticle radiosensitization.High dose bystander effects in spatially fractionated radiation therapy.Prostate cancer radiotherapy: potential applications of metal nanoparticles for imaging and therapy.Low-dose radiation-induced risk in spermatogenesis.Inhibition of ataxia telangiectasia related-3 (ATR) improves therapeutic index in preclinical models of non-small cell lung cancer (NSCLC) radiotherapy.FLIP: A Targetable Mediator of Resistance to Radiation in Non-Small Cell Lung Cancer.An overview of current practice in external beam radiation oncology with consideration to potential benefits and challenges for nanotechnology.Protein disulphide isomerase as a target for nanoparticle-mediated sensitisation of cancer cells to radiation.Time and Cell Type Dependency of Survival Responses in Co-cultured Tumor and Fibroblast Cells after Exposure to Modulated Radiation Fields.Conventional in vivo irradiation procedures are insufficient to accurately determine tumor responses to non-uniform radiation fields.Gold nanoparticle cellular uptake, toxicity and radiosensitisation in hypoxic conditions.Investigating the influence of respiratory motion on the radiation induced bystander effect in modulated radiotherapy.Biological consequences of nanoscale energy deposition near irradiated heavy atom nanoparticlesAn in vitro study of the radiobiological effects of flattening filter free radiotherapy treatments.Development of a novel experimental model to investigate radiobiological implications of respiratory motion in advanced radiotherapy.Relative biological effectiveness (RBE) and out-of-field cell survival responses to passive scattering and pencil beam scanning proton beam deliveries.In-vitro investigation of out-of-field cell survival following the delivery of conformal, intensity-modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) plans.Cell type-dependent uptake, localization, and cytotoxicity of 1.9 nm gold nanoparticles.Implications of intercellular signaling for radiation therapy: a theoretical dose-planning study.Dose, dose-rate and field size effects on cell survival following exposure to non-uniform radiation fields.A computational model of cellular response to modulated radiation fields.Cell survival responses after exposure to modulated radiation fields.Nanodosimetric effects of gold nanoparticles in megavoltage radiation therapy.Temporal characterization and in vitro comparison of cell survival following the delivery of 3D-conformal, intensity-modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT).Out-of-field cell survival following exposure to intensity-modulated radiation fields.A study of the biological effects of modulated 6 MV radiation fields.A mechanistic study of gold nanoparticle radiosensitisation using targeted microbeam irradiation.The role of mitochondrial function in gold nanoparticle mediated radiosensitisation.Mechanistic Rationale to Target PTEN-Deficient Tumor Cells with Inhibitors of the DNA Damage Response Kinase ATM.Modelling responses to spatially fractionated radiation fields using preclinical image-guided radiotherapy.Small field dosimetry for the small animal radiotherapy research platform (SARRP).Dual effects of radiation bystander signaling in urothelial cancer: purinergic-activation of apoptosis attenuates survival of urothelial cancer and normal urothelial cells.
P50
Q28066413-DA8819B1-D78F-4663-8DF4-4EFD52955AF5Q28728371-E6023CE8-557C-48F1-8C03-E3308B767767Q29248405-F03F732C-9B4E-42CF-80FF-15197E753BC2Q33792270-8C0E9375-6BEB-45D2-A102-4373148D5562Q34563252-E614AFB7-831D-43F0-8B0B-E36A27533DFEQ34776573-DF48E07E-50E0-42F7-98E6-80EFAE40E6D1Q35676729-D7DF7237-9C90-4062-AB78-4694476C13C6Q35898483-03BE687A-D332-4B4B-8717-832A639F449CQ38024325-32E09E8A-1B05-41A7-8412-483D4297BF4EQ38163718-99F96731-06B4-4042-B92F-797E5FCE049FQ38519540-185EDA4B-439D-4EDB-8BD9-D1EE6694A574Q38648574-A06AA5B5-540F-4A13-BED2-446DC499123FQ38697545-62A5B9BF-C175-45DD-8478-E96AC229C67FQ38754740-FFC3BEA6-E756-4581-94E3-2DEFC9B2FE66Q38755412-E10ABF09-0F28-46F6-B2A1-90EC44BE0CF2Q38778110-3CB0CE70-5AB4-4CEF-B635-859022B3AA92Q38874969-8C12FAB2-832A-4A6B-B9B2-3B16934AD9E7Q38944952-EEE8255F-4E68-47AE-A376-63001D75915EQ39032744-3BBBED18-B823-4966-9EEE-15FDF2EF5B40Q39064479-3B46E44C-9B6B-4A0C-90F0-C15CBB5A9389Q39119168-8F8ADFD9-4CD4-461F-996A-84B263A40569Q39196474-A1F15584-9F74-4991-8704-11B48C44E6BCQ39256700-842EC3F4-C3C0-4BB2-9A0F-21D3357F988EQ39269104-EA276544-C7A5-46DB-A278-0A4CE14D133CQ39269152-B5CB9AEC-A18A-4DE8-9832-286299F207BEQ39330773-A78A1EEB-0225-4D7B-B4ED-B5D997539435Q39334107-88D6ADBB-7C06-4E63-B727-3AE42BB001C9Q39356172-9747FCA2-B9B0-4935-B91C-A1932CB5F35BQ39405018-483484DE-E964-47D2-B95F-95D1F8385E82Q39452248-FFCBB430-F56D-4CB0-A72E-6BB477D30E72Q39472564-FBE1BBF8-688D-4F23-A04D-4573D9CA0745Q39572173-8DFCB4E1-C5FC-402D-9A74-586EC241CDE3Q39601056-07BC9468-5E58-4D05-900A-62C747A00CFFQ40064163-42F40F9D-4E61-4FDD-AEE8-D35A5DBC5BFCQ42315990-F8A0645F-A558-48F4-B1F7-771EE56C46CBQ42878512-134D7AF4-97DF-411E-9451-3D8B94C4F68FQ46682439-B465C77C-D100-439D-9852-0D74E3ECD7ECQ47105906-B31CAC29-3722-4FD6-8C0E-CF47E1668E94Q47241625-B9B27A19-09E0-4914-9DB9-B7D253889C1EQ47306677-A2D7798B-9723-4B8D-87E8-F8932EE27714
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Karl T Butterworth
@ast
Karl T Butterworth
@en
Karl T Butterworth
@es
Karl T Butterworth
@nl
type
label
Karl T Butterworth
@ast
Karl T Butterworth
@en
Karl T Butterworth
@es
Karl T Butterworth
@nl
prefLabel
Karl T Butterworth
@ast
Karl T Butterworth
@en
Karl T Butterworth
@es
Karl T Butterworth
@nl
P106
P1153
24464738400
P31
P496
0000-0001-7170-6789